GSA Capital Partners LLP Sells 118,426 Shares of Amylyx Pharmaceuticals, Inc. $AMLX

GSA Capital Partners LLP lowered its holdings in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 69.4% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 52,107 shares of the company’s stock after selling 118,426 shares during the quarter. GSA Capital Partners LLP’s holdings in Amylyx Pharmaceuticals were worth $708,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. California State Teachers Retirement System bought a new stake in Amylyx Pharmaceuticals during the second quarter valued at approximately $28,000. BNP Paribas Financial Markets boosted its stake in shares of Amylyx Pharmaceuticals by 433.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock worth $47,000 after acquiring an additional 5,904 shares during the last quarter. Ameritas Investment Partners Inc. bought a new stake in shares of Amylyx Pharmaceuticals during the 2nd quarter valued at $45,000. Legal & General Group Plc purchased a new stake in shares of Amylyx Pharmaceuticals in the 2nd quarter worth $47,000. Finally, Federated Hermes Inc. raised its holdings in Amylyx Pharmaceuticals by 4.1% in the 3rd quarter. Federated Hermes Inc. now owns 212,379 shares of the company’s stock worth $2,886,000 after purchasing an additional 8,449 shares during the period. Hedge funds and other institutional investors own 95.84% of the company’s stock.

Insider Buying and Selling at Amylyx Pharmaceuticals

In related news, CEO Joshua B. Cohen sold 1,974 shares of the firm’s stock in a transaction on Friday, January 16th. The shares were sold at an average price of $13.83, for a total transaction of $27,300.42. Following the completion of the transaction, the chief executive officer directly owned 3,379,465 shares of the company’s stock, valued at approximately $46,738,000.95. This trade represents a 0.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Justin B. Klee sold 1,995 shares of Amylyx Pharmaceuticals stock in a transaction on Friday, January 16th. The shares were sold at an average price of $13.89, for a total transaction of $27,710.55. Following the completion of the sale, the chief executive officer owned 3,379,398 shares in the company, valued at approximately $46,939,838.22. This represents a 0.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 157,783 shares of company stock worth $2,122,808. Insiders own 12.30% of the company’s stock.

Amylyx Pharmaceuticals Trading Down 0.1%

NASDAQ:AMLX opened at $14.01 on Friday. The stock has a 50-day moving average price of $13.47 and a 200 day moving average price of $12.79. The stock has a market capitalization of $1.54 billion, a P/E ratio of -7.78 and a beta of -0.31. Amylyx Pharmaceuticals, Inc. has a 12-month low of $2.60 and a 12-month high of $17.49.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Monday, December 29th. Bank of America lifted their price objective on Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the company a “buy” rating in a research report on Friday. Wall Street Zen downgraded Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. HC Wainwright increased their target price on shares of Amylyx Pharmaceuticals from $20.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, February 10th. Finally, Lifesci Capital raised shares of Amylyx Pharmaceuticals to a “strong-buy” rating in a report on Monday, October 27th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $18.63.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.